Gennex Laboratories Ltd (GENNEX) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Gennex Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
Gennex Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve 1. Consider and adopt the ....
Intimation · 14 Nov 2026, 5:30 am
Gennex Laboratories Schedules Board Meeting on 14th Nov'26 to Consider Q2 Results Gennex Laboratories Limited has scheduled a Board of Directors meeting on 14th Nov'26 to consider and adopt the unaudited standalone and consolidated financial results, along with the Statutory Auditor's Limited Review Reports, for the quarter and half-year ended 30th Sep'26. The company's trading window for dealing in securities, which closed on 1st Oct'26, will reopen 48 hours after the declaration of the financial results for all designated and connected persons.
In compliance to Regulation 44 of SEBI (LODR) Regulations, 2015, as amended from time to time, please find enclosed herewith voting results of the 41st eAGM of the Company held on September ....
Annual General Meeting · 01 Oct 2026, 7:53 pm
Pursuant to Regulation 30 read with Part A of Schedule III of SEBI (LODR) Regulations, 2015, we would like to inform you that the Company has received approval of its members by Special ....
Change in Management · 30 Sept 2026, 11:59 pm
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we are pleased to provide hereunder the proceedings of 41st eAGM of the Company held on Wednesday, September 30, 2026 through ....
Annual General Meeting · 30 Sept 2026, 11:43 pm
We are pleased to inform that our subsidiary company, M/s Deccan Remedies Limited has received approval from the Drugs Control Administration, Government of Andhra Pradesh granting License ....
Others (Uncategorized) · 08 Sept 2026, 11:07 pm
Gennex Laboratories Subsidiary Secures Manufacturing and Test Approvals in Andhra Pradesh Gennex Laboratories announced that its subsidiary, Deccan Remedies Limited, received manufacturing and test licence approvals from the Drug Control Administration, Government of Andhra Pradesh. Under Form 25, the company secured manufacturing and sales approvals for domestic and export markets covering six additional products: Caffeine, Duloxetine Hydrochloride, Mebeverine Hydrochloride, Phenylephrine Hydrochloride, Trimebutine Maleate, and Oxyclozanide, valid until 28th May'28. Furthermore, it obtained a three-year Form 29 test licence for four drugs—Ranolazine, Cinnarizine, Sacubitril, and Triclabendazole—to conduct examination, testing, and chemical analysis.
With reference to the subject matter, As per the Regulation 34 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we hereby submits 41st Annual Report of Gennex ....
Others (Uncategorized) · 08 Sept 2026, 8:31 pm
1. Draft Directors''/ Board Report for the Financial Year March 31, 2026; 2. The 41st Annual General Meeting of the Company to be held on Wednesday, September 30, 2026 at 12:30 P.M. through ....
Outcome · 04 Sept 2026, 10:55 pm
Gennex Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/09/2026 ,inter alia, to consider and approve 1. To decide regarding ....
Intimation · 27 Aug 2026, 11:25 pm
In just concluded Meeting of Board of Directors, the Board approved and considered the following items: 1. Unaudited Standalone and Consolidated Financial Statement for the Quarter ended ....
Financial Result · 14 Aug 2026, 10:39 pm
In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ....
Outcome · 14 Aug 2026, 10:26 pm
Gennex Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve 1. The Unaudited Financial ....
Intimation · 14 Aug 2026, 5:30 am
Gennex Laboratories Board Meeting Set for Aug'26 to Approve Q1FY27 Results Gennex Laboratories has scheduled a Board of Directors meeting for 14 Aug'26 to consider and approve its unaudited standalone and consolidated financial results for the quarter ended 30 Jun'26. The board will also review the statutory auditor's limited review report for the same period. The trading window, closed from 01 Jul'26, will reopen 48 hours after the results are declared.
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on June ....
Encumbered Shares - Invocation / Release · 10 Jun 2026, 10:10 pm
Gennex Labs Promoter Pledges Additional 1.03% Stake Promoter group entity Premier Fiscal Services Pvt. Ltd. pledged 25,00,000 equity shares (1.029% of total capital) of Gennex Laboratories on 09 Jun'26. The pledge was made in favour of Vidya Tradecon Pvt. Ltd. for availing a business loan. Post-transaction, the total encumbered shares held by the promoter entity increased from 4.116% to 5.145% of the company's total share capital. The promoter's total holding remains unchanged at 21.831%. The pledge expires on 07 Dec'26.
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on June ....
Encumbered Shares - Invocation / Release · 10 Jun 2026, 10:09 pm
Gennex Laboratories Promoter Pledges 1.03% Stake for Business Loan Promoter group entity Premier Fiscal Services Pvt. Ltd. has pledged 25,00,000 equity shares of Gennex Laboratories, representing 1.029% of total share capital. The pledge was created on 09 Jun'26 in favour of Vidya Tradecon Pvt. Ltd. to avail a business loan of Rs. 1.25 crore. Post-transaction, the total promoter encumbrance increased to 1,25,00,000 shares, which is 5.145% of the company's total share capital. The pledge is set to expire on 07 Dec'26.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 10, 2026 for Premier Fiscal Services Pvt Ltd
Encumbered Shares - Invocation / Release · 10 Jun 2026, 10:04 pm
Gennex Labs Promoter Pledges 1.03% Stake for Business Loan Promoter group entity Premier Fiscal Services Pvt. Ltd. has pledged 25,00,000 equity shares of Gennex Laboratories, representing 1.029% of total share capital. The pledge was created on 09-Jun-26 in favour of Vidya Tradecon Pvt. Ltd. to avail a business loan of Rs. 1,25,00,000. Post-transaction, Premier Fiscal's total encumbered holding in Gennex Labs increased to 1,25,00,000 shares, equivalent to 5.145% of the company's total share capital. The pledge is set to expire on 07-Dec-26.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 10, 2026 for Premier Fiscal Services Pvt Ltd
Encumbered Shares - Invocation / Release · 10 Jun 2026, 9:58 pm
Gennex Laboratories Promoter Pledges 1.03% Stake for Business Loan Promoter group entity Premier Fiscal Services Pvt. Ltd. pledged 25,00,000 equity shares (1.029% of total capital) of Gennex Laboratories on 09 Jun'26. The shares were pledged in favor of Vidya Tradecon Pvt. Ltd. to avail a business loan. Post-transaction, Premier Fiscal's total encumbered holding increased to 1,25,00,000 shares, representing 5.145% of the company's total share capital. The pledge is set to expire on 07 Dec'26. Premier Fiscal holds a total of 21.831% in Gennex Laboratories.
In just concluded Meeting of Board of Directors, the Board approved and considered the following items: 1. Audited Standalone & Consolidated Financial Results for the Quarter and Year ....
Financial Result · 31 May 2026, 1:28 am
Gennex Laboratories Q4FY26 Results: Strong Topline Growth and Qualified Audit Opinion Gennex Laboratories reported strong Q4FY26 consolidated results, with revenue at ₹60.96 Cr, up 51.2% YoY, and Net Profit at ₹4.46 Cr, up 45.4% YoY. For the full year FY26, revenue grew 25.4% YoY to ₹172.74 Cr, while Net Profit increased 15.7% to ₹20.98 Cr. However, the auditor issued a repetitive qualified opinion, citing an inability to verify balances of various current/non-current assets and liabilities due to a lack of confirmations. The financial impact of this qualification remains unascertainable.
In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Audited Standalone & Consolidated Financial results for the Quarter & Year Ended ....
Outcome · 31 May 2026, 1:14 am
Gennex Laboratories Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lacs) ■ Revenue: 6,096 (+51.2% YoY | +51.0% QoQ) ■ EBITDA: 589 (+192.3% YoY | -1.6% QoQ) ■ EBITDA Margin (%): 9.7 (+466 bps YoY | -517 bps QoQ) ■ PAT: 379 (+63.2% YoY | -27.6% QoQ) ■ EPS (INR): 0.16 (+17.3% YoY | -27.8% QoQ)
We refer to your email of 25th May, 2026 seeking clarification on your observation regarding significant movement noticed by the Exchange in the price of our company security at your exchange ....
Others (Uncategorized) · 26 May 2026, 10:36 pm
Gennex Laboratories Clarifies Stock Price Movement to BSE In response to a BSE query dated 25th May'26, Gennex Laboratories (BSE: 531739) has clarified recent significant stock price movement. The company confirmed on 26th May'26 that it has not made any price-sensitive announcements or shared material information in the public domain. Gennex attributes the price and volume changes to normal market behaviour and external factors, not undisclosed company information. The firm reiterated its commitment to promptly disclose any price-sensitive information to the exchange as required by regulations.
The Exchange has sought clarification from Gennex Laboratories Ltd on May 25, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Others (Uncategorized) · 25 May 2026, 11:43 pm
Gennex Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve With reference to the above ....
Intimation · 30 May 2026, 5:30 am
Gennex Laboratories Board Meeting to Approve FY26 Results on May 30 Gennex Laboratories will hold a Board of Directors meeting on 30 May'26 to consider and approve the audited standalone and consolidated financial results for the quarter and year ended 31 Mar'26. The agenda also includes reviewing the statutory auditor's reports on these financial statements. The trading window for designated persons, which closed on 01 Apr'26, will reopen 48 hours after the declaration of the financial results.
In compliance to Regulation 44 of SEBI (LODR) Regulations, 2015, as amended from time to time (Listing Regulations), please find enclosed herewith voting results of electronic Extraordinary ....
Extra Ordinary General Meeting · 13 May 2026, 9:38 pm
Gennex Laboratories EGM Resolution Passed with Overwhelming Majority Gennex Laboratories announced that all resolutions at its Extraordinary General Meeting on 12-May-'26 were passed with the requisite majority. The special resolution to regularize Ms. Khushbu Kachhawa as a Non-Executive Independent Woman Director was approved with 99.9997% of total valid votes in favour. The company disclosed that 31,176,049 votes were cast in favour versus only 87 against the resolution. Voting was conducted electronically, and promoter participation stood at 54.16% of their shareholding, with 100% of their votes cast in favour.
Pursuant to Reg.30 of SEBI (LODR) Regulations, 2015, we are pleased to provide hereunder the proceedings of Extraordinary General Meeting (EGM) of the Company held on Tuesday, May 12, 2026 ....
Extra Ordinary General Meeting · 12 May 2026, 8:33 pm
Gennex Labs EGM Focuses on Director Regularization Gennex Laboratories held an Extraordinary General Meeting (EGM) on 12 May'26 via video conference, attended by 47 members. The primary agenda was the regularization of Ms. Khushbu Kachhawa as a Non-Executive Independent Woman Director. The Chairman provided an overview of company operations and the outlook for the pharma sector. Remote e-voting was conducted from 08 May'26 to 11 May'26, with additional e-voting during the EGM. Results will be submitted to the stock exchanges post-scrutiny.
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 read with Schedule III and in furtherance to our intimation date April 16, 2026 and revised intimation dated April 17, 2026, we ....
Extra Ordinary General Meeting · 20 Apr 2026, 7:15 pm
Gennex Labs EGM on 12th May to Approve Independent Director Appointment Gennex Laboratories has scheduled an Extraordinary General Meeting (EGM) on 12th May'26 via video conference to seek shareholder approval for a key board appointment. The agenda includes the regularization of Ms. Khushbu Kachhawa as a Non-Executive Independent Woman Director. Ms. Kachhawa was appointed as an Additional Director on 14th Feb'26 following the resignation of Ms. Shilpa Bung. Her proposed term will run until the conclusion of the 45th AGM in 2030. The record date for e-voting eligibility is 01st May'26.
Revised outcome With reference to our earlier letter dated April 16, 2026, in this connection we would like to submit the revised outcome of the Board Meeting as follows: 1. Convening ....
Revision of outcome · 17 Apr 2026, 11:38 pm
Gennex Labs Sets EGM to Appoint Independent Director Gennex Laboratories will hold an Extraordinary General Meeting (EGM) on 12th May'26 to regularize the appointment of Ms. Khushbu Kachhawa as a Non-Executive Independent Woman Director. The e-voting period for the resolution is scheduled from 08th May'26 to 11th May'26, with a cut-off date of 01st May'26. The company appointed NSDL for e-voting services and Ms. Sweety Kapoor as the scrutinizer for the EGM. This follows the Board Meeting held on 16th Apr'26.
In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Convening of an Extraordinary General Meeting ('EGM') of the Company on Tuesday, ....
Outcome · 16 Apr 2026, 10:32 pm
Gennex Laboratories to Hold EGM for Director Regularization Gennex Laboratories’ board, in its meeting on 16 Apr'26, approved convening an Extraordinary General Meeting (EGM) on 12 May'26. The primary agenda is the regularization of Ms. Khushbu Kachhawa as a Non-Executive Independent Woman Director. The remote e-voting period for the EGM is scheduled from 09 May'26 to 11 May'26, with a cut-off date of 08 May'26 for determining shareholder eligibility. NSDL has been appointed as the e-voting agency for the meeting.